Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

15.11
-0.1250-0.82%
Volume:139.01K
Turnover:2.11M
Market Cap:1.39B
PE:-37.51
High:15.31
Open:15.13
Low:15.05
Close:15.23
Loading ...

PagerDuty Inc: Qtrly Revenue Was $121.4 Million

THOMSON REUTERS
·
14 Mar

PagerDuty Inc Outlook Q1 Non-Gaap Net Income per Diluted Share Attributable to PagerDuty, Inc. Common Stockholders of $0.18 - $0.19

THOMSON REUTERS
·
14 Mar

PagerDuty Q4 2025 Adj EPS $0.22 Beats $0.16 Estimate, Sales $121.40M Beat $119.77M Estimate

Benzinga
·
14 Mar

PagerDuty Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results

Business Wire
·
14 Mar

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

PR Newswire
·
13 Mar

Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
13 Mar

Press Release: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Dow Jones
·
13 Mar

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

GlobeNewswire
·
11 Mar

Investing in PagerDuty (NYSE:PD) five years ago would have delivered you a 31% gain

Simply Wall St.
·
11 Mar

PagerDuty Appoints Allison Corley as Chief Customer Officer

THOMSON REUTERS
·
11 Mar

PagerDuty Appoints Allison Corley as Chief Customer Officer

Business Wire
·
11 Mar

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

Business Wire
·
10 Mar

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
10 Mar

Lifeward (LFWD) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
07 Mar

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

GlobeNewswire
·
07 Mar

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

GlobeNewswire
·
06 Mar

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

GlobeNewswire
·
06 Mar

Box (BOX) Beats Q4 Earnings and Revenue Estimates

Zacks
·
05 Mar

Supernus to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
05 Mar

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

ACCESS Newswire
·
04 Mar